Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 418 articles:
HTML format



Single Articles


    October 2021
  1. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.
    PubMed    


    September 2021
  2. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    PubMed     Abstract available


  3. BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
    Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
    PubMed     Abstract available


  4. BERCIANO J
    Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
    J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.
    PubMed    


  5. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    PubMed     Abstract available


  6. HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
    Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    J Neurol. 2021;268:3125-3128.
    PubMed     Abstract available


  7. VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
    COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:3129-3131.
    PubMed    


    August 2021
  8. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    PubMed     Abstract available


  9. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    PubMed     Abstract available


  10. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    PubMed     Abstract available


  11. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    PubMed     Abstract available


  12. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    PubMed     Abstract available


  13. FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
    Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
    J Neurol. 2021;268:3011-3019.
    PubMed     Abstract available


  14. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    PubMed     Abstract available


  15. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    PubMed     Abstract available


  16. WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
    Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
    J Neurol. 2021;268:2700-2702.
    PubMed    


    July 2021
  17. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    PubMed     Abstract available


  18. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    PubMed     Abstract available


  19. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.
    PubMed    


  20. STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
    Sneddon syndrome: a comprehensive clinical review of 53 patients.
    J Neurol. 2021;268:2450-2457.
    PubMed     Abstract available


  21. MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
    A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
    J Neurol. 2021;268:2327-2330.
    PubMed     Abstract available


    June 2021
  22. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed     Abstract available


  23. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
    PubMed    


  24. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    PubMed    


  25. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed     Abstract available


  26. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    PubMed     Abstract available


  27. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
    PubMed    


  28. KIM SH, Baek SH, Lee SU, Yu S, et al
    Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
    J Neurol. 2021;268:2263-2266.
    PubMed    


  29. DAO LM, Machule ML, Bacher P, Hoffmann J, et al
    Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
    J Neurol. 2021;268:2123-2131.
    PubMed     Abstract available


  30. LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
    Bickerstaff encephalitis after COVID-19.
    J Neurol. 2021;268:2035-2037.
    PubMed    


    May 2021
  31. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed     Abstract available


  32. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed     Abstract available


  33. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    PubMed     Abstract available


  34. KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
    Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.
    PubMed    


  35. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    PubMed     Abstract available


  36. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    PubMed     Abstract available


  37. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    PubMed     Abstract available


  38. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    PubMed     Abstract available


  39. THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
    Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
    J Neurol. 2021;268:1818-1826.
    PubMed     Abstract available


    April 2021
  40. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    PubMed     Abstract available


  41. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    PubMed     Abstract available


  42. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    PubMed     Abstract available


  43. WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
    Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
    PubMed     Abstract available


  44. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    PubMed     Abstract available


  45. ZEIDAN S, Maillart E, Louapre C, Roux T, et al
    COVID-19 infection in NMO/SD patients: a French survey.
    J Neurol. 2021;268:1188-1190.
    PubMed    


  46. URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
    Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
    J Neurol. 2021;268:1536-1539.
    PubMed    


  47. KAPOOR M, Keh R, Compton L, Morrow S, et al
    Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    J Neurol. 2021;268:1485-1490.
    PubMed     Abstract available


  48. NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
    Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
    J Neurol. 2021;268:1419-1433.
    PubMed     Abstract available


  49. CHAUDHARY UJ, Rajabally YA
    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:1366-1373.
    PubMed     Abstract available


    March 2021
  50. MATHEY G, Pische G, Soudant M, Pittion-Vouyovitch S, et al
    Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.
    J Neurol. 2021 Mar 31. pii: 10.1007/s00415-021-10501.
    PubMed     Abstract available


  51. PINTER D, Kober SE, Fruhwirth V, Berger L, et al
    MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study.
    J Neurol. 2021 Mar 30. pii: 10.1007/s00415-021-10530.
    PubMed     Abstract available


  52. OZAWA Y, Uzawa A, Yasuda M, Kojima Y, et al
    Long-term outcomes and prognostic factors in generalized myasthenia gravis.
    J Neurol. 2021 Mar 27. pii: 10.1007/s00415-021-10520.
    PubMed     Abstract available


  53. SVACINA MKR, Kohle F, Sprenger A, Lehmann HC, et al
    Could symptom overlap of COVID-19 and Guillain-Barre syndrome mask an epidemiological association?
    J Neurol. 2021 Mar 17. pii: 10.1007/s00415-021-10515.
    PubMed    


  54. HJAERESEN S, Sejbaek T, Axelsson M, Vinslov-Jensen H, et al
    The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis.
    J Neurol. 2021 Mar 4. pii: 10.1007/s00415-021-10489.
    PubMed     Abstract available


  55. RATH J, Zulehner G, Schober B, Grisold A, et al
    Cerebrospinal fluid analysis in Guillain-Barre syndrome: value of albumin quotients.
    J Neurol. 2021 Mar 2. pii: 10.1007/s00415-021-10479.
    PubMed     Abstract available


  56. VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
    Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
    J Neurol. 2021;268:978-988.
    PubMed     Abstract available


  57. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
    J Neurol. 2021;268:879-890.
    PubMed     Abstract available


    February 2021
  58. GOUDOT M, Frismand S, Hopes L, Verger A, et al
    Recurrent seizures of autoimmune origin: emerging phenotypes.
    J Neurol. 2021 Feb 27. pii: 10.1007/s00415-021-10457.
    PubMed     Abstract available


  59. TOLEDANO-ILLAN C, Esparragosa Vazquez I, Zelaya Huerta MV, Rosales Castillo JJ, et al
    Autoimmune glial fibrillary acidic protein astrocytopathy: case report of a treatable cause of rapidly progressive dementia.
    J Neurol. 2021 Feb 26. pii: 10.1007/s00415-021-10484.
    PubMed    


  60. BUCELLO S, Annovazzi P, Ragonese P, Altieri M, et al
    Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    J Neurol. 2021 Feb 22. pii: 10.1007/s00415-021-10455.
    PubMed     Abstract available


  61. WALZL D, Solomon AJ, Stone J
    Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.
    J Neurol. 2021 Feb 21. pii: 10.1007/s00415-021-10436.
    PubMed     Abstract available


  62. CAPONE F, Ferraro E, Motolese F, Di Lazzaro V, et al
    COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10446.
    PubMed    


  63. FILIPPI M, Capra R, Centonze D, Gasperini C, et al
    Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10466.
    PubMed    


  64. JAKIMOVSKI D, Benedict RHB, Weinstock-Guttman B, Ozel O, et al
    Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?
    J Neurol. 2021 Feb 15. pii: 10.1007/s00415-021-10437.
    PubMed     Abstract available


  65. YOO JS, Kim YS, Kim HY, Kwon HS, et al
    Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
    J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
    PubMed     Abstract available


  66. MUNIZ-CASTRILLO S, Vogrig A, Montagnac C, Joubert B, et al
    Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study.
    J Neurol. 2021 Feb 5. pii: 10.1007/s00415-021-10424.
    PubMed     Abstract available


  67. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
    The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.
    J Neurol. 2021 Feb 1. pii: 10.1007/s00415-021-10400.
    PubMed     Abstract available


  68. MARTIN T, Duke S, Kumar V, Fadhil A, et al
    NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
    J Neurol. 2021;268:714-716.
    PubMed    


  69. SCHROTER N, Weiller C, Rauer S, Waller CF, et al
    Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
    J Neurol. 2021;268:709-711.
    PubMed    


  70. OKADA K, Seki M, Yaguchi H, Sakuta K, et al
    Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
    J Neurol. 2021;268:680-688.
    PubMed     Abstract available


  71. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    PubMed     Abstract available


    January 2021
  72. JORDAN B, Uer O, Buchholz T, Spens A, et al
    Physical fatigability and muscle pain in patients with Hashimoto thyroiditis.
    J Neurol. 2021 Jan 28. pii: 10.1007/s00415-020-10394.
    PubMed     Abstract available


  73. LUCCHINI M, Prosperini L, Buscarinu MC, Centonze D, et al
    Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    J Neurol. 2021 Jan 26. pii: 10.1007/s00415-021-10412.
    PubMed     Abstract available


  74. HARES K, Kemp K, Loveless S, Rice CM, et al
    KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.
    J Neurol. 2021 Jan 23. pii: 10.1007/s00415-020-10373.
    PubMed     Abstract available


  75. BOREMALM M, Sundstrom P, Salzer J
    Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10399.
    PubMed     Abstract available


  76. FAN Q, Hu Y, Wang X, Zhao B, et al
    Guillain-Barre syndrome in patients treated with immune checkpoint inhibitors.
    J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10404.
    PubMed     Abstract available


  77. CHISARI CG, Sgarlata E, Arena S, Toscano S, et al
    Rituximab for the treatment of multiple sclerosis: a review.
    J Neurol. 2021 Jan 8. pii: 10.1007/s00415-020-10362.
    PubMed     Abstract available


  78. KEVER A, Buyukturkoglu K, Riley CS, De Jager PL, et al
    Social support is linked to mental health, quality of life, and motor function in multiple sclerosis.
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10330.
    PubMed     Abstract available


  79. GELIBTER S, Pisa M, Croese T, Dalla Costa G, et al
    Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10322.
    PubMed     Abstract available


  80. ZHUO Z, Li Y, Duan Y, Cao G, et al
    Subtyping relapsing-remitting multiple sclerosis using structural MRI.
    J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10376.
    PubMed     Abstract available


  81. MONTE G, Spagni G, Damato V, Iorio R, et al
    Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
    J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10342.
    PubMed     Abstract available


  82. WOO MS, Steins D, Haussler V, Kohsar M, et al
    Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
    J Neurol. 2021;268:5-7.
    PubMed    


  83. STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
    Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
    J Neurol. 2021;268:367-376.
    PubMed     Abstract available


  84. KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
    Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
    J Neurol. 2021;268:265-275.
    PubMed     Abstract available


    December 2020
  85. NEMA E, Kalina A, Nikolai T, Vyhnalek M, et al
    Correction to: Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Dec 30. pii: 10.1007/s00415-020-10294.
    PubMed    


  86. NEUSS F, von Podewils F, Wang ZI, Susse M, et al
    Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy.
    J Neurol. 2020 Dec 15. pii: 10.1007/s00415-020-10346.
    PubMed     Abstract available


  87. MANTERO V, Rigamonti A, Basilico P, Crespi M, et al
    Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
    J Neurol. 2020;267:3465-3466.
    PubMed    


  88. ZACHARIADIS A, Tulbu A, Strambo D, Dumoulin A, et al
    Transverse myelitis related to COVID-19 infection.
    J Neurol. 2020;267:3459-3461.
    PubMed    


    November 2020
  89. PREZIOSA P, Rocca MA, Nozzolillo A, Moiola L, et al
    COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    J Neurol. 2020 Nov 20. pii: 10.1007/s00415-020-10309.
    PubMed    


  90. BRACAGLIA M, Naldi I, Govoni A, Brillanti Ventura D, et al
    Acute inflammatory demyelinating polyneuritis in association with an asymptomatic infection by SARS-CoV-2.
    J Neurol. 2020;267:3166-3168.
    PubMed    


    October 2020
  91. SIMONSEN CS, Flemmen HO, Broch L, Brunborg C, et al
    The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.
    J Neurol. 2020 Oct 22. pii: 10.1007/s00415-020-10279.
    PubMed     Abstract available


  92. ZECCA C, Disanto G, Sacco R, MacLachlan S, et al
    Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
    J Neurol. 2020 Oct 21. pii: 10.1007/s00415-020-10170.
    PubMed     Abstract available


  93. ARNETH B
    Contributions of T cells in multiple sclerosis: what do we currently know?
    J Neurol. 2020 Oct 20. pii: 10.1007/s00415-020-10275.
    PubMed     Abstract available


  94. LOTAN I, Hellmann MA, Wilf-Yarkoni A, Steiner I, et al
    Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.
    J Neurol. 2020 Oct 16. pii: 10.1007/s00415-020-10264.
    PubMed     Abstract available


  95. DOIG D, McNamara C, Mewasingh L, Beri S, et al
    Autoimmune cortical encephalitis in two children with anti-myelin oligodendrocyte glycoprotein (MOG) antibody.
    J Neurol. 2020 Oct 14. pii: 10.1007/s00415-020-10260.
    PubMed     Abstract available


  96. SRIWASTAVA S, Tandon M, Kataria S, Daimee M, et al
    New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.
    J Neurol. 2020 Oct 12. pii: 10.1007/s00415-020-10263.
    PubMed     Abstract available


  97. WILLIS MD, Robertson NP
    Multiple sclerosis: early indicators of disease and assessing future risk.
    J Neurol. 2020 Oct 8. pii: 10.1007/s00415-020-10239.
    PubMed    


  98. PARSONS T, Banks S, Bae C, Gelber J, et al
    COVID-19-associated acute disseminated encephalomyelitis (ADEM).
    J Neurol. 2020;267:2799-2802.
    PubMed     Abstract available


    September 2020
  99. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Sep 24. pii: 10.1007/s00415-020-10226.
    PubMed     Abstract available


  100. MONSCHEIN T, Salhofer-Polanyi S, Altmann P, Zrzavy T, et al
    Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.
    J Neurol. 2020 Sep 14. pii: 10.1007/s00415-020-10074.
    PubMed     Abstract available


  101. LEJEUNE F, Chatton A, Laplaud DA, Le Page E, et al
    SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.
    J Neurol. 2020 Sep 9. pii: 10.1007/s00415-020-10154.
    PubMed     Abstract available


  102. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.
    J Neurol. 2020 Sep 3. pii: 10.1007/s00415-020-10194.
    PubMed     Abstract available


  103. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis.
    J Neurol. 2020 Sep 2. pii: 10.1007/s00415-020-10195.
    PubMed     Abstract available


  104. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms.
    J Neurol. 2020 Sep 2. pii: 10.1007/s00415-020-10192.
    PubMed     Abstract available


  105. FERNANDEZ-DOMINGUEZ J, Ameijide-Sanluis E, Garcia-Cabo C, Garcia-Rodriguez R, et al
    Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19).
    J Neurol. 2020;267:2495-2496.
    PubMed    


    August 2020
  106. MANTERO V, Baroncini D, Balgera R, Guaschino C, et al
    Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
    J Neurol. 2020 Aug 31. pii: 10.1007/s00415-020-10196.
    PubMed    


  107. ZHANG J, Chen MJ, Zhao GX, Li HF, et al
    Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.
    J Neurol. 2020 Aug 29. pii: 10.1007/s00415-020-10184.
    PubMed     Abstract available


  108. ABU-RUMEILEH S, Abdelhak A, Foschi M, Tumani H, et al
    Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.
    J Neurol. 2020 Aug 25. pii: 10.1007/s00415-020-10124.
    PubMed     Abstract available


  109. CHIARAVALLOTI ND, Amato MP, Brichetto G, Chataway J, et al
    The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis.
    J Neurol. 2020 Aug 19. pii: 10.1007/s00415-020-10160.
    PubMed     Abstract available


  110. VICINI R, Brugger D, Abegg M, Salmen A, et al
    Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis.
    J Neurol. 2020 Aug 12. pii: 10.1007/s00415-020-10097.
    PubMed     Abstract available


  111. PELEA T, Reuter U, Schmidt C, Laubinger R, et al
    SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neurol. 2020 Aug 8. pii: 10.1007/s00415-020-10133.
    PubMed     Abstract available


  112. ASHTON K, Fuchs TA, Oship D, Zivadinov R, et al
    Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption.
    J Neurol. 2020 Aug 4. pii: 10.1007/s00415-020-10110.
    PubMed     Abstract available


  113. MARINI A, Vogrig A, Bax F, Pellitteri G, et al
    Reply to "GuillainBarre syndrome in the COVID19 era another occasional cluster?": Insights from two distinct clusters of Guillain-Barre syndrome detected in Europe in the COVID-19 era.
    J Neurol. 2020 Aug 4. pii: 10.1007/s00415-020-10006.
    PubMed    


  114. MUNZ M, Wessendorf S, Koretsis G, Tewald F, et al
    Acute transverse myelitis after COVID-19 pneumonia.
    J Neurol. 2020;267:2196-2197.
    PubMed    


    July 2020
  115. YUAN S, Xiong Y, Larsson SC
    An atlas on risk factors for multiple sclerosis: a Mendelian randomization study.
    J Neurol. 2020 Jul 29. pii: 10.1007/s00415-020-10119.
    PubMed     Abstract available


  116. ACHIRON A, Ben-David A, Gurevich M, Magalashvili D, et al
    Parity and disability progression in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10093.
    PubMed     Abstract available


  117. CAPUANO R, Altieri M, Bisecco A, d'Ambrosio A, et al
    Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10099.
    PubMed     Abstract available


  118. HAUER L, Perneczky J, Sellner J
    A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.
    J Neurol. 2020 Jul 27. pii: 10.1007/s00415-020-10107.
    PubMed     Abstract available


  119. EVA N, Adam K, Tomas N, Martin V, et al
    Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Jul 22. pii: 10.1007/s00415-020-10079.
    PubMed     Abstract available


  120. KALRON A, Menascu S, Hoffmann C, Achiron A, et al
    The importance of physical activity to preserve hippocampal volume in people with multiple sclerosis: a structural MRI study.
    J Neurol. 2020 Jul 22. pii: 10.1007/s00415-020-10085.
    PubMed     Abstract available


  121. LI V, Panicker JN, Haslam C, Chataway J, et al
    Use of a symptom-based questionnaire to screen for the presence of significant voiding dysfunction in patients with multiple sclerosis and lower urinary tract symptoms: a pilot study.
    J Neurol. 2020 Jul 16. pii: 10.1007/s00415-020-10068.
    PubMed     Abstract available


  122. MATEEN FJ, Rezaei S, Alakel N, Gazdag B, et al
    Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
    J Neurol. 2020 Jul 7. pii: 10.1007/s00415-020-10045.
    PubMed     Abstract available


  123. DE SITTER A, Verhoeven T, Burggraaff J, Liu Y, et al
    Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort.
    J Neurol. 2020 Jul 3. pii: 10.1007/s00415-020-10023.
    PubMed     Abstract available


  124. KAMINSKY AL, Omorou AY, Soudant M, Pittion-Vouyovitch S, et al
    Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.
    J Neurol. 2020 Jul 2. pii: 10.1007/s00415-020-10029.
    PubMed     Abstract available


  125. RICCITELLI GC, Pagani E, Meani A, Valsasina P, et al
    Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study.
    J Neurol. 2020 Jul 2. pii: 10.1007/s00415-020-10025.
    PubMed     Abstract available


  126. PFEFFERKORN T, Dabitz R, von Wernitz-Keibel T, Aufenanger J, et al
    Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19.
    J Neurol. 2020;267:1883-1884.
    PubMed    


  127. BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
    Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    J Neurol. 2020;267:2101-2114.
    PubMed     Abstract available


  128. MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
    Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
    J Neurol. 2020;267:1906-1911.
    PubMed     Abstract available


    June 2020
  129. BERCIANO J
    Axonal degeneration in Guillain-Barre syndrome: a reappraisal.
    J Neurol. 2020 Jun 30. pii: 10.1007/s00415-020-10034.
    PubMed     Abstract available


  130. MANTERO V, Abate L, Basilico P, Balgera R, et al
    COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
    J Neurol. 2020 Jun 25. pii: 10.1007/s00415-020-10015.
    PubMed    


  131. TATU L, Nono S, Gracio S, Kocer S, et al
    Guillain-Barre syndrome in the COVID-19 era: another occasional cluster?
    J Neurol. 2020 Jun 23. pii: 10.1007/s00415-020-10005.
    PubMed    


  132. VAN FAALS NL, Dekker I, Balk LJ, Moraal B, et al
    Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance.
    J Neurol. 2020 Jun 20. pii: 10.1007/s00415-020-09991.
    PubMed     Abstract available


  133. KOLANKO M, Win Z, Patel N, Malik O, et al
    Using amyloid PET imaging to diagnose Alzheimer's disease in patients with multiple sclerosis.
    J Neurol. 2020 Jun 18. pii: 10.1007/s00415-020-09969.
    PubMed     Abstract available


  134. GRANBERG T, Moridi T, Brand JS, Neumann S, et al
    Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis.
    J Neurol. 2020 Jun 13. pii: 10.1007/s00415-020-09971.
    PubMed     Abstract available


  135. VANDEBERGH M, Goris A
    Smoking and multiple sclerosis risk: a Mendelian randomization study.
    J Neurol. 2020 Jun 11. pii: 10.1007/s00415-020-09980.
    PubMed     Abstract available


  136. LEHMANN AI, Rodgers S, Kamm CP, Mettler M, et al
    Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study.
    J Neurol. 2020 Jun 11. pii: 10.1007/s00415-020-09973.
    PubMed     Abstract available


  137. FERRAZZANO G, Crisafulli SG, Baione V, Tartaglia M, et al
    Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.
    J Neurol. 2020 Jun 5. pii: 10.1007/s00415-020-09964.
    PubMed     Abstract available


  138. WELLER D, Filli L, Meyer C, Lorincz L, et al
    Impaired speed-dependent modulation of the gait pattern in multiple sclerosis.
    J Neurol. 2020 Jun 4. pii: 10.1007/s00415-020-09965.
    PubMed     Abstract available


  139. MAGHZI AH, Houtchens MK, Preziosa P, Ionete C, et al
    COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    J Neurol. 2020 Jun 3. pii: 10.1007/s00415-020-09944.
    PubMed     Abstract available


  140. PATTI F, Zimatore GB, Brescia Morra V, Aguglia U, et al
    Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    J Neurol. 2020;267:1812-1823.
    PubMed     Abstract available


  141. MIAO A, Liu Q, Li Z, Liu W, et al
    Altered cerebral blood flow in patients with anti-NMDAR encephalitis.
    J Neurol. 2020;267:1760-1773.
    PubMed     Abstract available


  142. CAROTENUTO A, Costabile T, De Lucia M, Moccia M, et al
    Predictors of Nabiximols (Sativex((R))) discontinuation over long-term follow-up: a real-life study.
    J Neurol. 2020;267:1737-1743.
    PubMed     Abstract available


  143. LOOS J, Pfeuffer S, Pape K, Ruck T, et al
    MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
    J Neurol. 2020;267:1632-1642.
    PubMed     Abstract available


    May 2020
  144. TOMASSINI V, Sinclair A, Sawlani V, Overell J, et al
    Diagnosis and management of multiple sclerosis: MRI in clinical practice.
    J Neurol. 2020 May 29. pii: 10.1007/s00415-020-09930.
    PubMed     Abstract available


  145. ANGELINI L, Hodgkinson W, Smith C, Dodd JM, et al
    Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09928.
    PubMed     Abstract available


  146. SIVAKOLUNDU DK, West KL, Zuppichini MD, Wilson A, et al
    BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non-specific white matter disease: a three-dimensional approach.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09923.
    PubMed     Abstract available


  147. MOHN N, Saker F, Bonda V, Respondek G, et al
    Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09921.
    PubMed    


  148. RIVA N, Russo T, Falzone YM, Strollo M, et al
    Post-infectious Guillain-Barre syndrome related to SARS-CoV-2 infection: a case report.
    J Neurol. 2020 May 26. pii: 10.1007/s00415-020-09907.
    PubMed    


  149. GOLD R, Radue EW, Giovannoni G, Selmaj K, et al
    Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
    J Neurol. 2020 May 25. pii: 10.1007/s00415-020-09835.
    PubMed     Abstract available


  150. WILLIAMS T, Zetterberg H, Chataway J
    Neurofilaments in progressive multiple sclerosis: a systematic review.
    J Neurol. 2020 May 23. pii: 10.1007/s00415-020-09917.
    PubMed     Abstract available


  151. MORRIS JK, Lopez-Leon S, Geissbuhler Y, Sabido M, et al
    A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.
    J Neurol. 2020 May 22. pii: 10.1007/s00415-020-09913.
    PubMed     Abstract available


  152. GIGLI GL, Bax F, Marini A, Pellitteri G, et al
    Guillain-Barre syndrome in the COVID-19 era: just an occasional cluster?
    J Neurol. 2020 May 19. pii: 10.1007/s00415-020-09911.
    PubMed    


  153. TSANTES E, Curti E, Ganazzoli C, Puci F, et al
    The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?
    J Neurol. 2020 May 12. pii: 10.1007/s00415-020-09894.
    PubMed     Abstract available


  154. KIM JG, Lee SU, Lee CN, Yu SW, et al
    Bilateral vestibulopathy as an early manifestation of systemic lupus erythematosus.
    J Neurol. 2020 May 11. pii: 10.1007/s00415-020-09876.
    PubMed    


  155. KOCH MW, Mostert J, Greenfield J, Liu WQ, et al
    Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent.
    J Neurol. 2020 May 9. pii: 10.1007/s00415-020-09895.
    PubMed     Abstract available


  156. DING J, Ren K, Wu J, Li H, et al
    Overlapping syndrome of MOG-IgG-associated disease and autoimmune GFAP astrocytopathy.
    J Neurol. 2020 May 7. pii: 10.1007/s00415-020-09869.
    PubMed     Abstract available


  157. COLOMBO C, Confalonieri P, Rovaris M, La Mantia L, et al
    The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis.
    J Neurol. 2020 May 2. pii: 10.1007/s00415-020-09864.
    PubMed     Abstract available


  158. BUKHARI W, Clarke L, O'Gorman C, Khalilidehkordi E, et al
    The clinical profile of NMOSD in Australia and New Zealand.
    J Neurol. 2020;267:1431-1443.
    PubMed     Abstract available


  159. MOLONEY PB, Hutchinson S, Heskin J, Mulcahy F, et al
    Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape.
    J Neurol. 2020;267:1348-1352.
    PubMed     Abstract available


  160. CARNERO CONTENTTI E, Daccach Marques V, Soto de Castillo I, Tkachuk V, et al
    Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    J Neurol. 2020;267:1260-1268.
    PubMed     Abstract available


  161. WENDEBOURG MJ, Nagy S, Derfuss T, Parmar K, et al
    Magnetic resonance imaging in immune-mediated myelopathies.
    J Neurol. 2020;267:1233-1244.
    PubMed     Abstract available


    April 2020
  162. CHEN MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, et al
    Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09853.
    PubMed     Abstract available


  163. SABIN J, Urtiaga S, Pilo B, Thuissard I, et al
    Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09848.
    PubMed     Abstract available


  164. MATEEN FJ, Vogel AC, Kaplan TB, Hotan GC, et al
    Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09845.
    PubMed     Abstract available


  165. PADRONI M, Mastrangelo V, Asioli GM, Pavolucci L, et al
    Guillain-Barre syndrome following COVID-19: new infection, old complication?
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09849.
    PubMed    


  166. MISICKA E, Sept C, Briggs FBS
    Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09850.
    PubMed     Abstract available


  167. GIBSON LL, McKeever A, Cullen AE, Nicholson TR, et al
    Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis.
    J Neurol. 2020 Apr 18. pii: 10.1007/s00415-020-09825.
    PubMed     Abstract available


  168. WILLIS MD, Robertson NP
    Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
    J Neurol. 2020 Apr 17. pii: 10.1007/s00415-020-09822.
    PubMed    


  169. MATTIOLI F, Bellomi F, Stampatori C, Mariotto S, et al
    Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients.
    J Neurol. 2020 Apr 15. pii: 10.1007/s00415-020-09832.
    PubMed     Abstract available


  170. TANG L, Huang Q, Qin Z, Tang X, et al
    Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.
    J Neurol. 2020 Apr 7. pii: 10.1007/s00415-020-09823.
    PubMed     Abstract available


  171. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    J Neurol. 2020 Apr 3. pii: 10.1007/s00415-020-09811.
    PubMed     Abstract available


  172. ZHANG W, Cui L, Zhang Y, Wang W, et al
    Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population.
    J Neurol. 2020;267:1197-1205.
    PubMed     Abstract available


  173. BOYKO M, Au KLK, Casault C, de Robles P, et al
    Systematic review of the clinical spectrum of CASPR2 antibody syndrome.
    J Neurol. 2020;267:1137-1146.
    PubMed     Abstract available


  174. SHI Z, Du Q, Chen H, Zhang Y, et al
    Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    J Neurol. 2020;267:913-924.
    PubMed     Abstract available


    March 2020
  175. CAROTENUTO A, Wilson H, Giordano B, Caminiti SP, et al
    Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.
    J Neurol. 2020 Mar 26. pii: 10.1007/s00415-020-09806.
    PubMed     Abstract available


  176. VISSING J, Jacob S, Fujita KP, O'Brien F, et al
    'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    J Neurol. 2020 Mar 18. pii: 10.1007/s00415-020-09770.
    PubMed     Abstract available


  177. SHEMA-SHIRATZKY S, Hillel I, Mirelman A, Regev K, et al
    A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity.
    J Neurol. 2020 Mar 12. pii: 10.1007/s00415-020-09759.
    PubMed     Abstract available


  178. GAVRILOV YV, Alekseeva TM, Kreis OA, Valko PO, et al
    Depression in myasthenia gravis: a heterogeneous and intriguing entity.
    J Neurol. 2020 Mar 5. pii: 10.1007/s00415-020-09767.
    PubMed     Abstract available


  179. SHANG P, Zhu M, Wang Y, Zheng X, et al
    Axonal variants of Guillain-Barre syndrome: an update.
    J Neurol. 2020 Mar 5. pii: 10.1007/s00415-020-09742.
    PubMed     Abstract available


  180. MARGONI M, Franciotta S, Poggiali D, Riccardi A, et al
    Cerebellar gray matter lesions are common in pediatric multiple sclerosis at clinical onset.
    J Neurol. 2020 Mar 5. pii: 10.1007/s00415-020-09776.
    PubMed     Abstract available


  181. ZUBER P, Tsagkas C, Papadopoulou A, Gaetano L, et al
    Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.
    J Neurol. 2020 Mar 2. pii: 10.1007/s00415-020-09768.
    PubMed     Abstract available


  182. BERARDO A, Emmanuele V, Vargas W, Tanji K, et al
    Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6.
    J Neurol. 2020;267:823-829.
    PubMed     Abstract available


  183. GIANNOCCARO MP, Di Stasi V, Zanesini C, Donadio V, et al
    Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation.
    J Neurol. 2020;267:739-745.
    PubMed     Abstract available


  184. HAMAGUCHI M, Suzuki K, Fujita H, Uzuka T, et al
    Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review.
    J Neurol. 2020;267:731-738.
    PubMed     Abstract available


    February 2020
  185. HELLWIG K, Geissbuehler Y, Sabido M, Popescu C, et al
    Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    J Neurol. 2020 Feb 26. pii: 10.1007/s00415-020-09762.
    PubMed     Abstract available


  186. MAGON S, Tsagkas C, Gaetano L, Patel R, et al
    Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
    J Neurol. 2020 Feb 10. pii: 10.1007/s00415-020-09740.
    PubMed     Abstract available


  187. SCHWEITZER F, Laurent S, Fink GR, Barnett MH, et al
    Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.
    J Neurol. 2020 Feb 8. pii: 10.1007/s00415-019-09690.
    PubMed     Abstract available


  188. KATSARI M, Kasselimis DS, Giogkaraki E, Breza M, et al
    A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?
    J Neurol. 2020 Feb 1. pii: 10.1007/s00415-020-09720.
    PubMed     Abstract available


  189. TANG MH, Mathis S, Duffau P, Cazenave P, et al
    Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort.
    J Neurol. 2020;267:561-571.
    PubMed     Abstract available


  190. SCHEIBE F, Ostendorf L, Reincke SM, Pruss H, et al
    Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis.
    J Neurol. 2020;267:317-323.
    PubMed     Abstract available


    January 2020
  191. NESS NH, Schriefer D, Haase R, Ettle B, et al
    Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.
    J Neurol. 2020 Jan 16. pii: 10.1007/s00415-019-09694.
    PubMed     Abstract available


  192. SHAH VV, McNames J, Mancini M, Carlson-Kuhta P, et al
    Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson's disease and matched controls during daily living.
    J Neurol. 2020 Jan 11. pii: 10.1007/s00415-020-09696.
    PubMed     Abstract available


  193. FREEDMAN MS, Brod S, Singer BA, Cohen BA, et al
    Clinical and MRI efficacy of sc IFN beta-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    J Neurol. 2020;267:64-75.
    PubMed     Abstract available


    December 2019
  194. NESS NH, Schriefer D, Haase R, Ettle B, et al
    Differentiating societal costs of disability worsening in multiple sclerosis.
    J Neurol. 2019 Dec 17. pii: 10.1007/s00415-019-09676.
    PubMed     Abstract available


  195. HEDSTROM AK, Olsson T, Kockum I, Hillert J, et al
    Low sun exposure increases multiple sclerosis risk both directly and indirectly.
    J Neurol. 2019 Dec 17. pii: 10.1007/s00415-019-09677.
    PubMed     Abstract available


  196. RATH J, Brunner I, Tomschik M, Zulehner G, et al
    Frequency and clinical features of treatment-refractory myasthenia gravis.
    J Neurol. 2019 Dec 11. pii: 10.1007/s00415-019-09667.
    PubMed     Abstract available


  197. DAVDA N, Tallantyre E, Robertson NP
    Early MRI predictors of prognosis in multiple sclerosis.
    J Neurol. 2019;266:3171-3173.
    PubMed    


    November 2019
  198. LIN WS, Wang HP, Chen HM, Lin JW, et al
    Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan.
    J Neurol. 2019 Nov 28. pii: 10.1007/s00415-019-09647.
    PubMed     Abstract available


  199. TAVAZZI E, Bergsland N, Kuhle J, Jakimovski D, et al
    A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    J Neurol. 2019 Nov 25. pii: 10.1007/s00415-019-09643.
    PubMed     Abstract available


  200. SIERRA MORALES F, Koralnik IJ, Gautam S, Samaan S, et al
    Correction to: Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Nov 23. pii: 10.1007/s00415-019-09626.
    PubMed     Abstract available


  201. BOURQUE PR, Brooks J, Warman-Chardon J, Breiner A, et al
    Cerebrospinal fluid total protein in Guillain-Barre syndrome variants: correlations with clinical category, severity, and electrophysiology.
    J Neurol. 2019 Nov 16. pii: 10.1007/s00415-019-09634.
    PubMed     Abstract available


  202. GRUTER T, Ott A, Meyer W, Jarius S, et al
    Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity by reliable specificity.
    J Neurol. 2019 Nov 14. pii: 10.1007/s00415-019-09614.
    PubMed     Abstract available


  203. PROSPERINI L, Cortese A, Lucchini M, Boffa L, et al
    Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.
    J Neurol. 2019 Nov 13. pii: 10.1007/s00415-019-09625.
    PubMed     Abstract available


  204. GOMEZ-FIGUEROA E, Garcia-Trejo S, Bazan-Rodriguez L, Cervantes-Uribe R, et al
    Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.
    J Neurol. 2019 Nov 12. pii: 10.1007/s00415-019-09622.
    PubMed     Abstract available


  205. LECLER A, Bouzad C, Deschamps R, Maizeroi F, et al
    Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.
    J Neurol. 2019;266:2786-2795.
    PubMed     Abstract available


  206. HERRAETS IJT, Bakers JNE, van Eijk RPA, Goedee HS, et al
    Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy.
    J Neurol. 2019;266:2734-2742.
    PubMed     Abstract available


    October 2019
  207. GIORDANO A, Fazio R, Gelibter S, Minicucci F, et al
    Diagnosing autoimmune encephalitis in a real-world single-centre setting.
    J Neurol. 2019 Oct 30. pii: 10.1007/s00415-019-09607.
    PubMed     Abstract available


  208. MIRAFZAL S, Goujon A, Deschamps R, Zuber K, et al
    3D PSIR MRI at 3 Tesla improves detection of spinal cord lesions in multiple sclerosis.
    J Neurol. 2019 Oct 26. pii: 10.1007/s00415-019-09591.
    PubMed     Abstract available


  209. RAMANATHAN S, Al-Diwani A, Waters P, Irani SR, et al
    The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis.
    J Neurol. 2019 Oct 26. pii: 10.1007/s00415-019-09590.
    PubMed     Abstract available


  210. FUJIMORI J, Fujihara K, Ogawa R, Baba T, et al
    Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis.
    J Neurol. 2019 Oct 25. pii: 10.1007/s00415-019-09595.
    PubMed     Abstract available


  211. PAPATHANASIOU A, Tanasescu R, Davis J, Rocha MF, et al
    MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity.
    J Neurol. 2019 Oct 22. pii: 10.1007/s00415-019-09586.
    PubMed     Abstract available


  212. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2019 Oct 17. pii: 10.1007/s00415-019-09568.
    PubMed     Abstract available


  213. SINNECKER T, Ruberte E, Schadelin S, Canova V, et al
    New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
    J Neurol. 2019 Oct 14. pii: 10.1007/s00415-019-09565.
    PubMed     Abstract available


  214. KAMM CP, Barin L, Gobbi C, Pot C, et al
    Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
    J Neurol. 2019 Oct 8. pii: 10.1007/s00415-019-09563.
    PubMed     Abstract available


  215. ROMEO MAL, Garassino MC, Moiola L, Galli G, et al
    Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    J Neurol. 2019 Oct 4. pii: 10.1007/s00415-019-09562.
    PubMed    


  216. MORALES FS, Koralnik IJ, Gautam S, Samaan S, et al
    Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Oct 3. pii: 10.1007/s00415-019-09557.
    PubMed     Abstract available


  217. BUDHRAM A, Mirian A, Le C, Hosseini-Moghaddam SM, et al
    Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome.
    J Neurol. 2019;266:2481-2487.
    PubMed     Abstract available


    September 2019
  218. MARGONI M, Rinaldi F, Riccardi A, Franciotta S, et al
    No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab.
    J Neurol. 2019 Sep 27. pii: 10.1007/s00415-019-09554.
    PubMed     Abstract available


  219. PAOLICELLI D, Lucisano G, Manni A, Avolio C, et al
    Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
    J Neurol. 2019 Sep 18. pii: 10.1007/s00415-019-09531.
    PubMed     Abstract available


  220. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2019 Sep 17. pii: 10.1007/s00415-019-09535.
    PubMed     Abstract available


  221. GRANELLA F, Tsantes E, Graziuso S, Bazzurri V, et al
    Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
    J Neurol. 2019 Sep 7. pii: 10.1007/s00415-019-09526.
    PubMed     Abstract available


  222. SHEMA-SHIRATZKY S, Gazit E, Sun R, Regev K, et al
    Deterioration of specific aspects of gait during the instrumented 6-min walk test among people with multiple sclerosis.
    J Neurol. 2019 Sep 6. pii: 10.1007/s00415-019-09500.
    PubMed     Abstract available


  223. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2019 Sep 3. pii: 10.1007/s00415-019-09498.
    PubMed     Abstract available


  224. CASTLE D, Robertson NP
    Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    J Neurol. 2019;266:2338-2340.
    PubMed    


  225. CHOUTEAU R, Combes B, Bannier E, Snoussi H, et al
    Joint assessment of brain and spinal cord motor tract damage in patients with early RRMS: predominant impact of spinal cord lesions on motor function.
    J Neurol. 2019;266:2294-2303.
    PubMed     Abstract available


  226. PUMA A, Azulay N, Grecu N, Suply C, et al
    Comparison of high-frequency and ultrahigh-frequency probes in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2019;266:2277-2285.
    PubMed     Abstract available


    August 2019
  227. STORELLI L, Rocca MA, Pantano P, Pagani E, et al
    MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis.
    J Neurol. 2019 Aug 17. pii: 10.1007/s00415-019-09509.
    PubMed     Abstract available


    July 2019
  228. INOJOSA H, Proschmann U, Akgun K, Ziemssen T, et al
    A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
    J Neurol. 2019 Jul 30. pii: 10.1007/s00415-019-09489.
    PubMed     Abstract available


  229. RASTAS C, Sirignano D, Barner A, Bruno-Murtha LA, et al
    Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
    J Neurol. 2019 Jul 26. pii: 10.1007/s00415-019-09483.
    PubMed    


  230. KIMURA K, Okada Y, Fujii C, Komatsu K, et al
    Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.
    J Neurol. 2019 Jul 24. pii: 10.1007/s00415-019-09461.
    PubMed     Abstract available


  231. MO XB, Lei SF, Qian QY, Guo YF, et al
    Integrative analysis revealed potential causal genetic and epigenetic factors for multiple sclerosis.
    J Neurol. 2019 Jul 18. pii: 10.1007/s00415-019-09476.
    PubMed     Abstract available


  232. MICHAEL G, Christian E, Fritz L, Jorg K, et al
    Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2019 Jul 16. pii: 10.1007/s00415-019-09464.
    PubMed     Abstract available


  233. RAIMO S, Trojano L, Gaita M, Spitaleri D, et al
    High openness and high extroversion are linked with better time-based prospective memory in multiple sclerosis.
    J Neurol. 2019 Jul 16. pii: 10.1007/s00415-019-09460.
    PubMed     Abstract available


  234. AYRIGNAC X, Rigau V, Lhermitte B, Vincent T, et al
    Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.
    J Neurol. 2019;266:1743-1755.
    PubMed     Abstract available


  235. TANI H, Nagai K, Hosokawa T, Hata K, et al
    Occurrence of cerebral small vessel disease at diagnosis of MPO-ANCA-associated vasculitis.
    J Neurol. 2019;266:1708-1715.
    PubMed     Abstract available


  236. KOGA M, Kishi M, Fukusako T, Ikuta N, et al
    Antecedent infections in Fisher syndrome: sources of variation in clinical characteristics.
    J Neurol. 2019;266:1655-1662.
    PubMed     Abstract available


    June 2019
  237. BERENGUER-RUIZ L, Gimenez-Martinez J, Palazon-Bru A, Sempere AP, et al
    Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    J Neurol. 2019 Jun 29. pii: 10.1007/s00415-019-09450.
    PubMed     Abstract available


  238. FRAU J, Sacca F, Signori A, Baroncini D, et al
    Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    J Neurol. 2019 Jun 17. pii: 10.1007/s00415-019-09424.
    PubMed     Abstract available


  239. SPARACO M, Lavorgna L, Bonavita S
    Psychiatric disorders in multiple sclerosis.
    J Neurol. 2019 Jun 13. pii: 10.1007/s00415-019-09426.
    PubMed     Abstract available


  240. CUNNIFFE N, Coles A
    Promoting remyelination in multiple sclerosis.
    J Neurol. 2019 Jun 12. pii: 10.1007/s00415-019-09421.
    PubMed     Abstract available


  241. KEARNS PKA, Paton M, O'Neill M, Waters C, et al
    Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register.
    J Neurol. 2019 Jun 11. pii: 10.1007/s00415-019-09413.
    PubMed     Abstract available


  242. SCHUSTER S, Ozga AK, Stellmann JP, Deb-Chatterji M, et al
    Relapse rates and long-term outcome in primary angiitis of the central nervous system.
    J Neurol. 2019;266:1481-1489.
    PubMed     Abstract available


    May 2019
  243. SODERHOLM J, Yilmaz A, Svenningsson A, Busch K, et al
    Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.
    J Neurol. 2019 May 31. pii: 10.1007/s00415-019-09397.
    PubMed     Abstract available


  244. LI H, Hu F, Zhang Y, Li K, et al
    Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09395.
    PubMed     Abstract available


  245. GAETANI L, Salvadori N, Lisetti V, Eusebi P, et al
    Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09398.
    PubMed     Abstract available


  246. DUDEK MIR, Thies K, Kammenhuber S, Bosel J, et al
    HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2019 May 21. pii: 10.1007/s00415-019-09391.
    PubMed    


  247. ALEKSEEVA TM, Kreis OA, Gavrilov YV, Valko PO, et al
    Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis.
    J Neurol. 2019 May 21. pii: 10.1007/s00415-019-09374.
    PubMed     Abstract available


  248. LANGENBRUCH L, Kramer J, Guler S, Moddel G, et al
    Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.
    J Neurol. 2019 May 8. pii: 10.1007/s00415-019-09332.
    PubMed     Abstract available


  249. PANTAVOU KG, Bagos PG
    Season of birth and multiple sclerosis: a systematic review and multivariate meta-analysis.
    J Neurol. 2019 May 4. pii: 10.1007/s00415-019-09346.
    PubMed     Abstract available


  250. ZIFF OJ, Hoskote C, Keddie S, D'Sa S, et al
    Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome.
    J Neurol. 2019;266:1067-1072.
    PubMed     Abstract available


  251. WYNFORD-THOMAS R, Jacob A, Tomassini V
    Neurological update: MOG antibody disease.
    J Neurol. 2019;266:1280-1286.
    PubMed     Abstract available


    April 2019
  252. PUST GEA, Pottgen J, Randerath J, Lau S, et al
    In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients.
    J Neurol. 2019 Apr 19. pii: 10.1007/s00415-019-09311.
    PubMed     Abstract available


  253. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Retraction Note to: Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2019 Apr 11. pii: 10.1007/s00415-019-09292.
    PubMed     Abstract available


  254. SPINA E, Topa A, Iodice R, Tozza S, et al
    Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP.
    J Neurol. 2019;266:860-865.
    PubMed     Abstract available


    March 2019
  255. SINGH N, Goyal V
    Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    J Neurol. 2019 Mar 27. pii: 10.1007/s00415-019-09296.
    PubMed     Abstract available


  256. GAO J, Jones J, Damato EM, Coles A, et al
    Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    J Neurol. 2019 Mar 20. pii: 10.1007/s00415-019-09288.
    PubMed    


  257. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: frequency and prognosis.
    J Neurol. 2019 Mar 15. pii: 10.1007/s00415-019-09273.
    PubMed    


  258. FRAU J, Coghe G, Lorefice L, Fenu G, et al
    Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    J Neurol. 2019 Mar 12. pii: 10.1007/s00415-019-09272.
    PubMed     Abstract available


  259. NYE CJS, Wagner A, Kousin-Ezewu O, Jones JL, et al
    A case of anaphylaxis to alemtuzumab.
    J Neurol. 2019;266:780-781.
    PubMed    


  260. SHAYGANNEJAD V, Fayyazi E, Badihian S, Mirmosayyeb O, et al
    Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
    J Neurol. 2019;266:642-650.
    PubMed     Abstract available


    February 2019
  261. TURNER B, Cree BAC, Kappos L, Montalban X, et al
    Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
    J Neurol. 2019 Feb 28. pii: 10.1007/s00415-019-09248.
    PubMed     Abstract available


  262. RICHTER S, Wagner B, Celius EG
    Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
    J Neurol. 2019 Feb 25. pii: 10.1007/s00415-019-09257.
    PubMed    


  263. PERSSON R, Lee S, Yood MU, Wagner M, et al
    Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries.
    J Neurol. 2019 Feb 18. pii: 10.1007/s00415-019-09238.
    PubMed     Abstract available


  264. JAKIMOVSKI D, Weinstock-Guttman B, Gandhi S, Guan Y, et al
    Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.
    J Neurol. 2019 Feb 13. pii: 10.1007/s00415-019-09208.
    PubMed     Abstract available


  265. MASSA R, Greco G, Testi M, Rastelli E, et al
    Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.
    J Neurol. 2019 Feb 11. pii: 10.1007/s00415-019-09225.
    PubMed     Abstract available


  266. BLATTNER MS, de Bruin GS, Bucelli RC, Day GS, et al
    Sleep disturbances are common in patients with autoimmune encephalitis.
    J Neurol. 2019 Feb 11. pii: 10.1007/s00415-019-09230.
    PubMed     Abstract available


  267. LEBRUN-FRENAY C, Moulignier A, Pierrot-Deseilligny C, Benrabah R, et al
    Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    J Neurol. 2019 Feb 7. pii: 10.1007/s00415-019-09211.
    PubMed     Abstract available


  268. KIM SW, Choi YC, Kim SM, Shim HS, et al
    Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis.
    J Neurol. 2019 Feb 6. pii: 10.1007/s00415-019-09222.
    PubMed     Abstract available


  269. GAMRAOUI S, Mathey G, Debouverie M, Malaplate C, et al
    High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.
    J Neurol. 2019 Feb 1. pii: 10.1007/s00415-019-09212.
    PubMed     Abstract available


  270. LAURIDO-SOTO O, Brier MR, Simon LE, McCullough A, et al
    Patient characteristics and outcome associations in AMPA receptor encephalitis.
    J Neurol. 2019;266:450-460.
    PubMed     Abstract available


  271. RAJABALLY YA, Afzal S
    Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2019;266:461-467.
    PubMed     Abstract available


  272. FISSE AL, Pitarokoili K, Motte J, Gamber D, et al
    Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2019;266:468-475.
    PubMed     Abstract available


  273. D'AMICO E, Zanghi A, Sciandra M, Borriello G, et al
    Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
    J Neurol. 2019;266:411-416.
    PubMed     Abstract available


  274. CHALMER TA, Kalincik T, Laursen B, Sorensen PS, et al
    Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    J Neurol. 2019;266:306-315.
    PubMed     Abstract available


    January 2019
  275. ALCALA C, Gascon F, Perez-Miralles F, Dominguez JA, et al
    Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    J Neurol. 2019 Jan 19. pii: 10.1007/s00415-019-09195.
    PubMed     Abstract available


  276. LAVORGNA L, Esposito S, Lanzillo R, Sparaco M, et al
    Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.
    J Neurol. 2019 Jan 16. pii: 10.1007/s00415-019-09193.
    PubMed     Abstract available


  277. TOPAKIAN R, Zimprich F, Iglseder S, Embacher N, et al
    High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
    J Neurol. 2019 Jan 16. pii: 10.1007/s00415-019-09191.
    PubMed     Abstract available


  278. HARTUNG HP, Graf J, Kremer D
    Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.
    J Neurol. 2019 Jan 4. pii: 10.1007/s00415-018-09169.
    PubMed     Abstract available


  279. PFEUFFER S, Schmidt R, Straeten FA, Pul R, et al
    Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
    J Neurol. 2019;266:165-173.
    PubMed     Abstract available


    December 2018
  280. SONG J, Westerlind H, McKay KA, Almqvist C, et al
    Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study.
    J Neurol. 2018 Dec 21. pii: 10.1007/s00415-018-9163.
    PubMed     Abstract available


  281. AL-HAKEM H, Sindrup SH, Andersen H, de la Cour CD, et al
    Guillain-Barre syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity.
    J Neurol. 2018 Dec 7. pii: 10.1007/s00415-018-9151.
    PubMed     Abstract available


  282. JOHNEN A, Burkner PC, Landmeyer NC, Ambrosius B, et al
    Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).
    J Neurol. 2018 Dec 4. pii: 10.1007/s00415-018-9142.
    PubMed     Abstract available


  283. BRAUNE S, Grimm S, van Hovell P, Freudensprung U, et al
    Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    J Neurol. 2018;265:2980-2992.
    PubMed     Abstract available


  284. FALZONE YM, Campagnolo M, Bianco M, Dacci P, et al
    Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies.
    J Neurol. 2018;265:2927-2933.
    PubMed     Abstract available


  285. DORST J, Ludolph AC, Senel M, Tumani H, et al
    Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.
    J Neurol. 2018;265:2906-2915.
    PubMed     Abstract available


    November 2018
  286. MEGNA R, Alfano B, Lanzillo R, Costabile T, et al
    Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    J Neurol. 2018 Nov 29. pii: 10.1007/s00415-018-9139.
    PubMed     Abstract available


  287. KILJAN S, Meijer KA, Steenwijk MD, Pouwels PJW, et al
    Structural network topology relates to tissue properties in multiple sclerosis.
    J Neurol. 2018 Nov 22. pii: 10.1007/s00415-018-9130.
    PubMed     Abstract available


  288. HARDING KE, Robertson NP
    New rare genetic variants in multiple sclerosis.
    J Neurol. 2018 Nov 20. pii: 10.1007/s00415-018-9128.
    PubMed    


  289. RIEDERER I, Muhlau M, Hoshi MM, Zimmer C, et al
    Detecting optic nerve lesions in clinically isolated syndrome and multiple sclerosis: double-inversion recovery magnetic resonance imaging in comparison with visually evoked potentials.
    J Neurol. 2018 Nov 16. pii: 10.1007/s00415-018-9114.
    PubMed     Abstract available


  290. BAUMGARTNER A, Rauer S, Hottenrott T, Leypoldt F, et al
    Admission diagnoses of patients later diagnosed with autoimmune encephalitis.
    J Neurol. 2018 Nov 12. pii: 10.1007/s00415-018-9105.
    PubMed     Abstract available


  291. SAEZ MS, Rojas JI, Lorenzon MV, Sanchez F, et al
    Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires.
    J Neurol. 2018 Nov 1. pii: 10.1007/s00415-018-9106.
    PubMed     Abstract available


  292. STAMPANONI BASSI M, Iezzi E, Landi D, Monteleone F, et al
    Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.
    J Neurol. 2018;265:2540-2547.
    PubMed     Abstract available


    October 2018
  293. ELLRICHMANN G, Bolz J, Peschke M, Duscha A, et al
    Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.
    J Neurol. 2018 Oct 30. pii: 10.1007/s00415-018-9092.
    PubMed     Abstract available


  294. MCLAUGHLIN L, Clarke L, Khalilidehkordi E, Butzkueven H, et al
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol. 2018 Oct 3. pii: 10.1007/s00415-018-9074.
    PubMed     Abstract available


  295. TOMMASIN S, De Giglio L, Ruggieri S, Petsas N, et al
    Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.
    J Neurol. 2018 Oct 1. pii: 10.1007/s00415-018-9075.
    PubMed     Abstract available


    September 2018
  296. PROSPERINI L, Annovazzi P, Boffa L, Buscarinu MC, et al
    No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    J Neurol. 2018 Sep 26. pii: 10.1007/s00415-018-9070.
    PubMed     Abstract available


  297. TUDOR KI, Eames S, Haslam C, Chataway J, et al
    Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.
    J Neurol. 2018 Sep 19. pii: 10.1007/s00415-018-9064.
    PubMed     Abstract available


  298. LI F, Hotter B, Swierzy M, Ismail M, et al
    Generalization after ocular onset in myasthenia gravis: a case series in Germany.
    J Neurol. 2018 Sep 17. pii: 10.1007/s00415-018-9056.
    PubMed     Abstract available


  299. FAKIH R, Matiello M, Chitnis T, Stankiewicz JM, et al
    Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    J Neurol. 2018 Sep 10. pii: 10.1007/s00415-018-9050.
    PubMed     Abstract available


  300. GAETANI L, Prosperini L, Mancini A, Eusebi P, et al
    2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.
    J Neurol. 2018 Sep 8. pii: 10.1007/s00415-018-9048.
    PubMed     Abstract available


  301. LY LT, Kreye J, Jurek B, Leubner J, et al
    Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9042.
    PubMed     Abstract available


  302. CAMBRON M, Reynders T, Debruyne J, Reyngoudt H, et al
    Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, (1)H and (31)P MRS, and clinical and cognitive testing.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9039.
    PubMed     Abstract available


  303. VAN LIEVERLOO GGA, Peric S, Doneddu PE, Gallia F, et al
    Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.
    J Neurol. 2018;265:2052-2059.
    PubMed     Abstract available


    August 2018
  304. FILSER M, Schreiber H, Pottgen J, Ullrich S, et al
    The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.
    J Neurol. 2018 Aug 31. pii: 10.1007/s00415-018-9034.
    PubMed     Abstract available


  305. BABER U, Bouley A, Egnor E, Sloane JA, et al
    Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
    J Neurol. 2018 Aug 14. pii: 10.1007/s00415-018-8996.
    PubMed     Abstract available


  306. ALEKSEEVA TM, Gavrilov YV, Kreis OA, Valko PO, et al
    Fatigue in patients with myasthenia gravis.
    J Neurol. 2018 Aug 11. pii: 10.1007/s00415-018-8995.
    PubMed     Abstract available


  307. RUMPF JJ, Dietrich S, Stoppe M, Fricke C, et al
    Compromised tDCS-induced facilitation of motor consolidation in patients with multiple sclerosis.
    J Neurol. 2018 Aug 6. pii: 10.1007/s00415-018-8993.
    PubMed     Abstract available


  308. SEITZ CB, Droby A, Zaubitzer L, Kramer J, et al
    Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.
    J Neurol. 2018 Aug 2. pii: 10.1007/s00415-018-8988.
    PubMed     Abstract available


  309. MALLUCCI G, Annovazzi P, Miante S, Torri-Clerici V, et al
    Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    J Neurol. 2018;265:1850-1859.
    PubMed     Abstract available


  310. CAO D, Guo X, Yuan T, Hao J, et al
    Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique.
    J Neurol. 2018;265:1916-1921.
    PubMed     Abstract available


    July 2018
  311. FROHLICH K, Winder K, Linker RA, Huhn K, et al
    Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.
    J Neurol. 2018 Jul 31. pii: 10.1007/s00415-018-8989.
    PubMed     Abstract available


  312. COCOZZA S, Pontillo G, Russo C, Russo CV, et al
    Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?
    J Neurol. 2018 Jul 28. pii: 10.1007/s00415-018-8985.
    PubMed     Abstract available


  313. BALLOY G, Pelletier J, Suchet L, Lebrun C, et al
    Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
    J Neurol. 2018 Jul 27. pii: 10.1007/s00415-018-8984.
    PubMed     Abstract available


  314. BARONE S, Caligiuri ME, Valentino P, Cherubini A, et al
    Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study.
    J Neurol. 2018 Jul 26. pii: 10.1007/s00415-018-8980.
    PubMed     Abstract available


  315. GALGANI S, Prosperini L, Haggiag S, Tortorella C, et al
    Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
    J Neurol. 2018 Jul 17. pii: 10.1007/s00415-018-8976.
    PubMed    


  316. BOST C, Chanson E, Picard G, Meyronet D, et al
    Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.
    J Neurol. 2018 Jul 12. pii: 10.1007/s00415-018-8970.
    PubMed     Abstract available


  317. ALADRO Y, Lopez-Alvarez L, Sanchez-Reyes JM, Hernandez-Tamames JA, et al
    Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis.
    J Neurol. 2018 Jul 11. pii: 10.1007/s00415-018-8965.
    PubMed     Abstract available


  318. KALLWEIT U, Bassetti CLA, Oberholzer M, Fronczek R, et al
    Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review.
    J Neurol. 2018 Jul 4. pii: 10.1007/s00415-018-8949.
    PubMed     Abstract available


    June 2018
  319. BAJRAMI A, Pitteri M, Castellaro M, Pizzini F, et al
    The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    J Neurol. 2018 Jun 25. pii: 10.1007/s00415-018-8952.
    PubMed     Abstract available


  320. MOTTE J, Kneiphof J, Strassburger-Krogias K, Klasing A, et al
    Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.
    J Neurol. 2018 Jun 15. pii: 10.1007/s00415-018-8931.
    PubMed     Abstract available


    May 2018
  321. MARSHALL I, Thrippleton MJ, Bastin ME, Mollison D, et al
    Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8903.
    PubMed     Abstract available


  322. WAGNER JN, Schwarz G, Puttinger G, Hengsberger AM, et al
    Anti-NMDA receptor encephalitis triggered by epilepsy surgery.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8918.
    PubMed    


  323. YAMAGUCHI H, Sakai K, Goto Y, Yamada M, et al
    Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis.
    J Neurol. 2018 May 29. pii: 10.1007/s00415-018-8912.
    PubMed    


  324. SANTANGELO G, Bisecco A, Trojano L, Sacco R, et al
    Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.
    J Neurol. 2018 May 26. pii: 10.1007/s00415-018-8905.
    PubMed     Abstract available


  325. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Abstract available


  326. KOCSIK AS, Klein DE, Liedke M, Kaunzner UW, et al
    Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    J Neurol. 2018;265:1226-1229.
    PubMed     Abstract available


  327. OPFER R, Ostwaldt AC, Walker-Egger C, Manogaran P, et al
    Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    J Neurol. 2018;265:1158-1165.
    PubMed     Abstract available


  328. TALLANTYRE EC, Whittam DH, Jolles S, Paling D, et al
    Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
    J Neurol. 2018;265:1115-1122.
    PubMed     Abstract available


    April 2018
  329. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Abstract available


  330. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Abstract available


  331. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Abstract available


  332. CABRE P, Mejdoubi M, Jeannin S, Merle H, et al
    Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    J Neurol. 2018;265:917-925.
    PubMed     Abstract available


    March 2018
  333. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Abstract available


  334. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Abstract available


  335. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Abstract available


  336. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Abstract available


  337. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Abstract available


  338. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Abstract available


  339. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Abstract available


  340. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Abstract available


  341. KANEKO A, Kaneko J, Tominaga N, Kanazawa N, et al
    Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis.
    J Neurol. 2018;265:586-596.
    PubMed     Abstract available


    February 2018
  342. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Abstract available


  343. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Abstract available


  344. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.
    PubMed    


  345. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Abstract available


  346. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Abstract available


  347. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Abstract available


  348. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Abstract available


  349. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Abstract available


  350. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Abstract available


  351. FRAU J, Carai M, Coghe G, Fenu G, et al
    Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    J Neurol. 2018;265:410-416.
    PubMed     Abstract available


  352. AKDAL G, Tanriverdizade T, Sengun I, Bademkiran F, et al
    Vestibular impairment in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2018;265:381-387.
    PubMed     Abstract available


  353. WANG R, Lai XH, Liu X, Li YJ, et al
    Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.
    J Neurol. 2018;265:362-369.
    PubMed     Abstract available


  354. HONGELL K, Silva DG, Ritter S, Meier DP, et al
    Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
    J Neurol. 2018;265:348-355.
    PubMed     Abstract available


    January 2018
  355. VOGRIG A, Joubert B, Ducray F, Thomas L, et al
    Glioblastoma as differential diagnosis of autoimmune encephalitis.
    J Neurol. 2018 Jan 30. pii: 10.1007/s00415-018-8767.
    PubMed     Abstract available


  356. GILHUS NE, Romi F, Hong Y, Skeie GO, et al
    Myasthenia gravis and infectious disease.
    J Neurol. 2018 Jan 25. pii: 10.1007/s00415-018-8751.
    PubMed     Abstract available


  357. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Abstract available


  358. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Abstract available


  359. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Abstract available


  360. MCMACKEN G, Whittaker RG, Evangelista T, Abicht A, et al
    Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients.
    J Neurol. 2018;265:194-203.
    PubMed     Abstract available


  361. ALENDA R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, et al
    Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
    J Neurol. 2018;265:24-31.
    PubMed     Abstract available


    December 2017
  362. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Abstract available


  363. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Abstract available


  364. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Abstract available


    November 2017
  365. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Abstract available


  366. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Abstract available


  367. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Abstract available


  368. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Abstract available


    October 2017
  369. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Abstract available


  370. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Abstract available


  371. ABBOUD H, Rossman I, Mealy MA, Hill E, et al
    Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    J Neurol. 2017 Oct 3. doi: 10.1007/s00415-017-8627.
    PubMed     Abstract available


    September 2017
  372. WANG L, Zhang S, Xi J, Li W, et al
    Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616.
    PubMed     Abstract available


  373. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Abstract available


  374. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Abstract available


    August 2017
  375. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Abstract available


  376. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed    


  377. FINKE C, Bartels F, Lutt A, Pruss H, et al
    High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8582.
    PubMed     Abstract available


    July 2017
  378. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Abstract available


  379. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jul 10. doi: 10.1007/s00415-017-8556.
    PubMed    


    June 2017
  380. CASEY JP, Hirouchi T, Hisatsune C, Lynch B, et al
    A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.
    J Neurol. 2017 Jun 15. doi: 10.1007/s00415-017-8545.
    PubMed     Abstract available


  381. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541.
    PubMed     Abstract available


  382. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Abstract available


    May 2017
  383. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Abstract available


  384. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Abstract available


  385. RATH J, Mauritz M, Zulehner G, Hilger E, et al
    Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8518.
    PubMed     Abstract available


  386. RIVIERE E, Cohen Aubart F, Maisonobe T, Maurier F, et al
    Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.
    J Neurol. 2017 May 23. doi: 10.1007/s00415-017-8519.
    PubMed     Abstract available


  387. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Abstract available


  388. CORDTS I, Bodart N, Hartmann K, Karagiorgou K, et al
    Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8514.
    PubMed     Abstract available


  389. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Abstract available


    April 2017
  390. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Abstract available


  391. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Abstract available


  392. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Abstract available


  393. CHOI HA, Lee MJ, Chung CS
    Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
    J Neurol. 2017;264:724-732.
    PubMed     Abstract available


  394. BARTOLINI L, Muscal E
    Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    J Neurol. 2017;264:647-653.
    PubMed     Abstract available


    March 2017
  395. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2017 Mar 31. doi: 10.1007/s00415-017-8478.
    PubMed     Abstract available


  396. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed    


  397. MCLAUCHLAN D, Robertson NP
    B cell treatments for multiple sclerosis.
    J Neurol. 2017 Mar 4. doi: 10.1007/s00415-017-8442.
    PubMed    


  398. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Abstract available


    February 2017
  399. NIJ BIJVANK JA, Balk LJ, Tan HS, Uitdehaag BM, et al
    A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.
    J Neurol. 2017 Feb 13. doi: 10.1007/s00415-017-8412.
    PubMed    


  400. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed    


    January 2017
  401. BIANCHI A, Bartolini E, Melani F, Guerrini R, et al
    Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
    J Neurol. 2017;264:179-181.
    PubMed    


    December 2016
  402. GIORLI E, Franciotta D, Beronio A, Amodeo C, et al
    Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.
    J Neurol. 2016;263:2549-2551.
    PubMed    


  403. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Abstract available


  404. HUANG Q, Wu Y, Qin R, Wei X, et al
    Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    J Neurol. 2016;263:2446-2455.
    PubMed     Abstract available


    November 2016
  405. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Abstract available


    October 2016
  406. PIETRZAK K, Grzybowski A, Kaczmarczyk J
    Georges Guillain (1876-1961).
    J Neurol. 2016;263:2148-9.
    PubMed    


  407. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Abstract available


    September 2016
  408. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed    


  409. LOZERON P, Ribrag V, Adams D, Brisset M, et al
    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?
    J Neurol. 2016;263:1761-70.
    PubMed     Abstract available


  410. ANNOVAZZI P, Capobianco M, Moiola L, Patti F, et al
    Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    J Neurol. 2016;263:1727-35.
    PubMed     Abstract available


    August 2016
  411. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Abstract available


    July 2016
  412. ZHOU H, Zhao S, Yin D, Chen X, et al
    Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
    J Neurol. 2016;263:1382-9.
    PubMed     Abstract available


  413. JEONG IH, Kim HJ, Kim NH, Jeong KS, et al
    Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
    J Neurol. 2016;263:1343-8.
    PubMed     Abstract available


  414. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Abstract available


  415. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Abstract available


    June 2016
  416. BRIER MR, Day GS, Snyder AZ, Tanenbaum AB, et al
    N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.
    J Neurol. 2016;263:1083-91.
    PubMed     Abstract available


  417. GRIMM A, Vittore D, Schubert V, Rasenack M, et al
    Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    J Neurol. 2016;263:1074-82.
    PubMed     Abstract available


    May 2016
  418. VINJAM MR, Shanmugarajah P, Ford HL
    Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.
    J Neurol. 2016;263:1017-8.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: